Immuneering is focused on improving patient outcomes by improving a pipeline of oncology and neuroscience product candidates developed using Co.'s translational bioinformatics platform. Co.'s development programs in oncology is focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and mTOR pathways. Co.'s primary product candidate, IMM-1-104, is designed to be a selective dual-mitogen-activated protein kinase kinase inhibitor that further disrupts kinase suppressor of RAS 1 and 2 to modulate the signaling dynamics of the MAPK pathway. In addition to IMM-1-104, Co. has six other oncology programs in the discovery stage. We show 10 historical shares outstanding datapoints in our IMRX shares outstanding history coverage, used to compute IMRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMRX market cap history over the course of time is important for investors
interested in comparing IMRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMRX versus a peer is one thing; comparing
IMRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMRX can fluctuate over the course of history.
With this page we aim to empower investors researching IMRX by allowing them to research the IMRX market cap history. |
Free IMRX Email Alerts:
Video: The Importance of Market Cap
